Introduction to pre-treatment assessment

All people living with HCV infection should be considered for treatment, except those with limited life expectancy (< 12 months) due to non-liverrelated or non-HCV-related comorbidities. It is important that all people considered for treatment undergo a comprehensive pre-treatment assessment (Table 2). This assessment provides the foundation for a successful virological outcome by establishing a therapeutic and collaborative relationship.

Key elements of the pre-treatment assessment are:

  • Perform a virological evaluation to:

    • confirm the diagnosis of chronic HCV infection

    • identify the genotype of HCV infection

    • document the HCV treatment history
  • Evaluate for the presence of cirrhosis

  • Evaluate for the presence of hepatitis B virus (HBV) or human immunodeficiency virus (HIV) coinfection

  • Consider whether there are coexisting liver diseases present

  • Consider concomitant medications for risk of drug–drug interactions, including over-the-counter preparations and recreational substances. 

  • Evaluate renal function

  • Discuss the need for contraception

Tags: CCK

PrintEmail